| Date | Title | Description |
| 18.02.2022 | CryoTherapeutics receives additional funding of € 12.3 million and launches a new clinical study | Awans, Belgium, 17 February 2022 - CryoTherapeutics, focusing on the development, demonstration of clinical benefit, and early-stage commercialization of a proprietary cryotherapy system for use in the treatmentof coronary artery disease th... |
| - | Wunderflats closes €3 million investment to establish “Housing as a Service” | Wunderflats (wunderflats.com), a leading online platform for furnished apartments, raises €3 million from Creathor Venture, the IBB Beteiligungsgesellschaft’s VC Fonds Kreativwirtschaft, ECONA AG and family offices. The financing round serv... |
| - | Deloitte: Tenant apps such as Allthings' allow for 70% efficiency gains | Basel, October 2nd, 2017 – Tenant apps are not only designed to improve tenant communication and achieve a corresponding boost in customer satisfaction, but to optimize workflows as well. Deloitte uses a model calculation to examine whether... |
| - | #MakeItTen: Interview with Sirion Biotech | In part three of this little series called #MakeItTen, we interviewed Dieter Lingelbach from Sirion Biotech. Sirion is an investment out of our CV II fund. Enjoy reading and as always, fell free to share. |
| - | #MakeItTen: Interview with vasopharm | Make It Ten №5 is with Christian Wandersee, CEO of the most recent investment of our CV IV fund: vasopharm. Hopefully, as a private person, you will never have to deal with the product vasopharm is developing, but if you do, it might save y... |
| - | Creathor and private investors invest CHF 2.5 million in PropTech company Allthings | Basel/Bad Homburg v.d.H., June 20, 2017 – Creathor Venture, a leading pan-European venture capital firm, together with a circle of experienced private investors from the real estate industry invest CHF 2.5 million in German-Swiss property t... |
| - | CEVEC, medac and Provecs Medical enter a collaboration in oncology | Cologne, Wedel and Hamburg, Germany, March 16, 2017 – CEVEC Pharmaceuticals GmbH (CEVEC), the expert in the production of tailor-made recombinant glycoproteins and gene therapy vectors, Provecs Medical GmbH (Provecs), a biopharmaceutical co... |
| - | Creathor invests in genetic diagnostic company Blueprint Genetics | Bad Homburg v.d.H., July 11th, 2017 – Creathor Venture announced today that it is leading a financing round for Helsinki, Finland-based Blueprint Genetics. The company is an internationally successful provider of clinical genetic testing fo... |
| - | $12 Million Series A for HeyJobs: From “Post-and-Pray” to Predictable Hiring™ | BERLIN, Germany. 8 May 2019 |
| - | AYOXXA launches kits for fully scalable multiplex protein analysis | Cologne, Germany, June 4th, 2018 - AYOXXA Biosystems GmbH, an international biotechnology company offering a range of products and services which enable advances in translational proteomics, today announced the expansion of its catalogue of... |
| - | AYOXXA launches LUNARIS Mouse 12-Plex Th17 Kit | AYOXXA Biosystems GmbH, an international biotechnology company, focused on the development of innovative multiplex protein analysis technologies enabling translational research in basic and clinical research, today announced the expansion o... |
| - | #MakeItTen: Interview with Acousia Therapeutics | Hello, can you hear me? CAN YOU HEAR ME? If not, this is probably because you are reading this. But actually an estimated 10–15 % of us in the developed world suffer from hearing impairment, predominantly caused by the irreversible loss of ... |
| - | Prostatype Genomics strengthens its product offering by launching P-score Web Service (PWS) | Solna, Sweden March 25th, 2021 - Using PWS, physicians and other healthcare professionals worldwide can easily access P-score, the Company’s unique method for prognosis of prostate cancer. |
| - | Creathor joins SICTIC | Swiss startups may look forward to larger sums in their seed financing rounds. Creathor Ventures with over EUR 230 million under management has joined the Swiss ICT Investor Club (SICTIC) as preferred co-investor. |
| - | #MakeItTen: Interview with CEVEC Pharmaceuticals | In part №10 of our interview series, we sat down with Dr. Nicole Faust, CEO & CSO of CEVEC Pharmaceuticals to talk about AAV vectors, the importance of enthusiasm for the success of a company, golf and much more. Enjoy reading! |
| - | Allthings raises CHF 13.7 million in Series A funding round | Basel, Switzerland/Berlin, Germany, July 12, 2018 - The German-Swiss PropTech company Allthings closes its Series A with 13.7 Million Swiss Francs led by Earlybird and Idinvest Partners as well as Kingstone Capital Partners. With the partic... |
| - | Successful Exit for Creathor Ventures – ArchiMed buys Cube Biotech GmbH | Bad Homburg, 3.11.2021 – Creathor Ventures announced that the trans-atlantic private equity healthcare specialist ArchiMed has purchased a majority stake in Monheim, Germany-based Cube Biotech GmbH. Founded with an early-stage investment by... |
| - | vasopharm announces Last Patient Last Visit in NOSTRA III Traumatic Brain Injury Clinical Trial Copy | Würzburg,Germany – 1st July, 2020 - vasopharm GmbH, a privately held biopharmaceutical company focusing on novel therapeutics for the treatment of cerebrovascular diseases, is pleased to announce today that the Last Patient Last Visit (LPLV... |
| - | Cédric talks about AI, buzzwords and more in an interview with Startus magazine | Cédric Köhler, Managing Partner at Creathor Venture, a pan-European fund currently managing more than EUR 220 million, talks about their most successful investment so far and explains why Artificial Intelligence is 2017′s buzzword. |
| - | lengoo, the German AI-first translation tech company, raises €6M additional funding | lengoo supplies more than 3,000 of the biggest companies in Europe with AI-powered translation services in over 400 language combinations. Its highly innovative training approach of neural networks on the basis of clients’ language data has... |
| - | Allthings implements digital solution at business properties of Credit Suisse Global Real Estate | In March 2017 the Global Real Estate group of Credit Suisse Asset Management (Schweiz) AG decided to have its entire service portfolio from the LIVING SERVICES residential segment presented via the Allthings platform. Now, for the first tim... |
| - | Creathor Ventures portfolio company Prostatype Genomics AB's pre-IPO securities issue oversubscribed | Solna/SwedenOctober 6, 2020 -The pre-IPO subscription period in Prostatype Genomics AB's ("Prostatype Genomics" or "the Company") issue of securities, consisting of shares and associated warrants, prior to listing at Nas... |
| - | CEVEC licenses CAP® technologies for Zika virus vaccines | Agreement marks an important step in establishing CAP(R) technologies as the new global industrial standard for viral vector and vaccine development |
| - | Successful Exit for Creathor Ventures, High-Tech Gründerfonds, Bayern Kapital and KfW– PerkinElmer agrees to acquire Viral Vector Gene Delivery Leader SIRION Biotech | Bonn, June 23rd, 2021 – Creathor Ventures, High-Tech Gründerfonds, KfW and Bayern Kapital announced that they are committed to sell their shares of SIRION Biotech GmbH, a global provider of viral vector-based technologies that drive improve... |
| - | #MakeItTen: Interview with Allthings Technologies | Have you ever asked yourself why any kind of communication with your landlord or your property manager has to be such a pain in the neck? And why there is no tool or platform to communicate with the other tenants in your building? Allthings... |
| - | #MakeItTen: Interview with R3 Communications | They have created a new generation of wireless transmission technology and are ready to disrupt entire industries. Get to know Berlin-based start-up R3 — Reliable Realtime Radio Communications with their first product EchoRing and see how R... |
| - | CEVEC closes growth financing round to serve strong demand in viral vector technologies for cell and gene therapies | Cologne, Germany, July 27th, 2021 - CEVEC Pharmaceuticals GmbH (CEVEC), the leading provider of high-performance cell technology for scalable manufacturing of advanced bio-therapeutics, today announced the successful closing of an internal ... |
| - | Cédric talks about Creathor’s strategy in Berlin Valley | “For more than seven fund generations, our focus has been on tech and life sciences now as well as on the constantly increasing intersection of these two areas (e.g., digital health). There are not many VCs in Europe who can do both.”
Creat... |
| - | SmartBear aquires our portfolio company Bitbar | HELSINKI, FINLAND, August 29, Bitbar Technologies, the leading provider of testing technology for web and mobile applications, has been acquired by SmartBear Software.
Bitbar has been developing best-in-class testing solutions for over ten ... |
| - | Karlheinz answers questions about biotech investment trends | Karlheinz Schmelig im Interview mit Holger Garbs, Plattform Life Sciences |
| - | Creathor invests in decentralised database start-up Haja Networks | Creathor Ventures becomes an investor in Haja Networks, joining Outlier Ventures and Polychain Capital. The funding round also features Berlin-based BigchainDB. |
| - | Sirion breakthrough technology improves genetic stem cell therapies | (Martinsried, 12.01.2017) With the beginning of a new fiscal year SIRION Biotech GmbH, located at the Innovation and Start-Up Center for Biotechnology in Martinsried/Planegg near Munich, reports an annual growth of 140% to 4 million Euros i... |
| - | 8 million euro investment for Wunderflats, Germany's leading platform for Housing as a Service | Berlin, July 11, 2019 - Everyone should be able to live and work wherever they want - this is the vision of the company Wunderflats, Germany’s leading marketplace for temporary furnished housing, or “Housing as a Service” as they call it. T... |
| - | CEVEC and PlasmidFactory announce collaboration regarding AAV production | CEVEC Pharmaceuticals GmbH (CEVEC), the expert in the production of tailor-made recombinant glycoproteins and gene therapy vectors, today announced that the Company will collaborate with PlasmidFactory, the leading contract manufacturer and... |
| - | iFunded raises €4 million growth capital to extend its offer to institutional investors | iFunded, one of Germanys leading digital real estate investment platforms and the first to offer investments to institutional investors, announces a 4 million Euro Pre-Series A round of financing led by EVAN Group plc. along with former hea... |
| - | Equity management platform Ledgy secures 1 million euros for expansion in Europe | European investor consortium led by btov Partners invests in equity software for private companies |
| - | Creathor Ventures successfully exited portfolio company Blueprint Genetics | Secaucus, N.J, USA and Helsinki, Finland – January 22, 2020 -- Quest Diagnostics acquired Blueprint Genetics in an all-cash equity transaction. Blueprint Genetics is a leading specialty genetic testing company with deep expertise in gene va... |
| - | CEVEC closes financing round to expand its viral vector manufacturing platform | Cologne, Germany, April 16, 2019 – CEVEC Pharmaceuticals GmbH (CEVEC), the expert in the production of tailor-made recombinant glycoproteins and gene therapy vectors, today announced the successful closing of a Series D financing round with... |
| - | R3 selected to join Startup Autobahn Program #2 | Berlin, February 21st, 2017 – R3Coms, the R3 – Reliable Realtime Radio Communications GmbH, has been selected by the jury of Startup Autobahn to take part in its Program #2 starting in March 2017. The decision was made after the participati... |
| - | Tacalyx Raises â¬7 Million to Generate Anti-TACA Antibodies for Cancer Treatment | Tacalyx, a biotech company focused on the discovery and development of novel anti-TACA (Tumor Associated Carbohydrate Antigens) cancer therapies, today announced that it has successfully secured €7 million in seed funding. The funding round... |
| - | SIRION Biotech and Acucela Set Sights on Gene Delivery Tools for Ocular Gene Therapy | Munich, January 8th, 2018 — SIRION Biotech GmbH (“SIRION”), a world leader in virus based technology innovation and gene delivery expert providing custom services to commercial partners worldwide, announced today that it signed a two year d... |
| - | CEVEC and Rznomics sign license agreement for the use of CAP® Technology in manufacturing of adenoviral vectors | Cologne, Germany and Yongin, Korea, October 19, 2020 - CEVEC Pharmaceuticals GmbH (CEVEC) and Rznomics Inc. (Rznomics) today announced the signing of a clinical and commercial license agreement for the use of CEVEC’s proprietary CAP® Techno... |
| - | CryoTherapeutics closes Series B financing round at EUR 7 million | Awans, Belgium and Cologne, Germany – CryoTherapeutics GmbH and CryoTherapeutics SA today announced the closing of its B round of financing. The funding will be used to support the Company’s clinical trials programme and to establish operat... |
| - | Karlheinz elaborates on the chances of personalized medicine | Every year billions of euros are wasted on medicines that have no effect on the patient. Even worse, quite a few medications even cause serious side effects. However, such medications are still widely prescribed. But since regulatory agenci... |
| - | Karlheinz on the marathon trade sale exit of Sividon | “The trade sale of Sividon to Myriad was the result of some kind of a marathon run consisting of years of negotiations and two M & A processes at the end of which the selling price was more than 100 percent above the first offer.”
Creat... |
| - | CEVEC and CellGenix announce the launch of GMP-grade TGF-ß1 for cell and gene therapy applications | Cologne and Freiburg, Germany, December 19, 2019 - CEVEC Pharmaceuticals GmbH (CEVEC), the expert in tailor-made recombinant glycoproteins and gene therapy vectors, today announced that the Company’s cooperation partner CellGenix GmbH, a le... |
| - | CEVEC signs license agreement for the development and commercialization of exosomes for therapeutic use | Cologne, Germany, April 16, 2020 - CEVEC Pharmaceuticals GmbH (CEVEC) today announced the signing ofa license agreement with Evox Therapeutics, Ltd. (Evox) for the development andcommercialization of therapeutic exosomes using CEVEC's propr... |
| - | #MakeItTen: Interview with lengoo | Make It Ten is the attempt to give the fantastic founders and/or CEOs of our portfolio companies the possibility to present their “babies” to a bigger audience and at the same time share a little bit of their knowledge and experiences they ... |
| - | SIRION Biotech Announces Record First Half 2019 Financial Results | MUNICH–SIRION Biotech GmbH (“SIRION”), a world leader in viral vector-based gene delivery technologies for gene and cell therapy, today announced financial results for the first half of 2019. SIRION’s viral vector technologies make breakthr... |
| - | CEVEC and CSL Limited sign exclusive license agreement | Cologne, Germany and Melbourne, Asutralia, May 8, 2018 – CEVEC Pharmaceuticals GmbH (CEVEC), the expert in the production of tailor-made recombinant glycoproteins and gene therapy vectors, and global biotechnology leader CSL Limited (ASX:CS... |
| - | Creathor's portfolio company Alrise Biosystems announces acquisition of its ImSus® drug delivery technology by Ferring International. | Berlin/Germany December 14, 2020 -The drug delivery specialist Alrise Biosystems GmbH has entered into an Asset Purchase and Exclusive License Agreement with Ferring International Center S.A. for the development and commercialisation of pro... |
| - | CEVEC announces the launch of the ELEVECTA® Platform – the Stable Producer Cell Line Technology for AAV Gene Therapy Vectors | Cologne, Germany, April 28th, 2020 - CEVEC Pharmaceuticals GmbH (CEVEC), the leading provider of high-performance cell technology for the manufacturing of advanced biotherapeutics from research to production scale, today announced the launc... |
| - | Cevec signs agreement with Roche for the use of Cevec’s Elevecta® Technology in Gene Therapy | Cologne, Germany, November 10, 2020 - CEVEC Pharmaceuticals GmbH (CEVEC) today announced the signing of an option and license agreement with Roche for the use of its newly launched ELEVECTA® Technology for large scale manufacturing of adeno... |
| - | Creathor invests in Swedish high-tech start-up Adaptive Simulations | Stockholm/Bad Homburg v.d.H., May 4th, 2017 – Creathor Venture, leading European venture capital firm in the high-tech space, announced today that they invest 1.5 million euros in Adaptive Simulations together with Estonian VC Karma Venture... |
| - | Wunderflats receives $21 million in growth funding to make it easier for people to access housing in Europe | Berlin, June 25th 2021 – Wunderflats, the leading platform for temporary furnished housing in Germany, announces a $21 million growth funding round to further pursue their vision to create a more accessible and convenient housing market acr... |
| - | Creathor and IBB Bet invest in R3 Communications | Berlin/Bad Homburg v.d.H., January 23, 2017 – Creathor Venture, one of the leading European venture capital firms,together withVC FondsTechnologie Berlin, managed by IBB Beteiligungsgesellschaft, joins Berlin high-tech start-up R3 Communica... |
| - | CEVEC and CARISMA Therapeutics sign license agreement for the use of CAP® Technology in anti-tumor cell therapies | Cologne, Germany and Philadelphia, PA, USA February 2, 2021 - CEVEC Pharmaceuticals GmbH (CEVEC) and CARISMA Therapeutics Inc. (CARISMA) today announced the signing of an agreement which grants CARISMA a clinical and commercial license for ... |
| - | Creathor invests in ehealth platform „HUMANOO“ | Berlin/Bad Homburg v.d.H., January 30, 2017 – Creathor Ventures, together with Dieter von Holtzbrinck Ventures (DvH Ventures), Rheingau Founders, Rocket Internet and other investors, invests a significant seven-digit amount in HUMANOO, the ... |
| - | CEVEC announces new license agreement for its AAV manufacturing technology ELEVECTA® in gene therapy | Cologne,Germany, January 8, 2021 - CEVEC Pharmaceuticals GmbH (CEVEC) today announced the signing of a license agreement with Biogen Inc. (Biogen; Nasdaq: BIIB) for the use of CEVEC’s proprietary ELEVECTA® Technology for the manufacturing o... |
| - | Phenex announces milestone payment from Janssen | Phenex drug discovery has now resulted in two clinical stage programs this year through research collaborations |
| - | Cédric shares his take on venture capital with Deutsche-Startups.de | “We see ourselves as a very active and dedicated partner. We have the know-how and a network of more than 30 years in the venture capital sector to support our portfolio companies,” says Cédric Köhler, Managing Partner at Creathor Venture, ... |
| - | Creathor invests in Acousia Therapeutics to fight hearing loss in â¬10 million financing round | Creathor Ventures announced today that it has, together with other investors, invested close to EUR 10 million in a Series B investment round in Acousia Therapeutics GmbH. Acousia is a Tübingen/Germany-based leader in the discovery and deve... |
| - | #MakeItTen: Interview with HeyJobs | We are back with another episode of Make It Ten, this time interviewing Marius Luther from HeyJobs. The AI-powered programmatic Talent
Acquisition Platform, which recently raised a $12 million Series A round, is an investment from our CV II... |
| - | #MakeItTen: Interview with Ledgy | In the second interview of our portfolio interview series #MakeItTen, YokoSpirig answers our nine questions and asks us one herself. Yoko is co-founder and CPO at Ledgy, the new standard in equity management. Enjoy reading and feel free to ... |
| - | Blueprint Genetics launches open digital platform to connect clinicians | Helsinki, April 12, 2018 – The aim of the Nucleus Connecting Clinicians Open platform is to make rare genomic data accessible to health care professionals around the world. This platform provides them with the opportunity to share knowledge... |
| - | Blueprint Genetics strengthens its pharmaceutical expertise with new Chairman and a Senior Advisor | Blueprint Genetics has gained worldwide momentum and continued global growth in the field of clinical genetic testing of rare inherited diseases. As one of the fastest growing clinical genetic testing businesses globally, Blueprint Genetics... |
| - | SIRION Biotech and Denali Therapeutics Join Forces | MUNICH - SIRION Biotech GmbH, a world leader in viral vector-based gene delivery technologies for gene & cell therapy, announced today that it signed a license and collaboration agreement with Denali Therapeutics, a biopharmaceutical co... |
| - | Phenex receives $100 million milestone payment from Gilead | Ludwigshafen, Germany, January 06, 2017 – Phenex Pharmaceuticals AG (Phenex) yesterday announced that the company has received a 100 M USD milestone payment from Gilead Sciences, Inc. of Foster City, CA, U.S.A., for its program with GS-9674... |
| - | SIRION Biotech announces collaboration with Sanofi to innovate gene therapy treatments with improved adeno-associated virus capsids | MUNICH, Germany, February 23, 2021—SIRION Biotech GmbH, a world leader in viral vector-based gene delivery technologies for gene & cell therapy, announced today that it signed a license and collaboration agreement with Sanofi, a global ... |
| - | Ledgy launches free employee participation templates for Swiss startups | Zurich, May 27th 2018 - According to a recent study by Index Ventures, European startup employees own half of the amount US employees own of their companies in terms of equity (source). This could be one of the main reasons why Europe has n... |
| - | #MakeItTen: Interview with Imverse | Anybody out there old enough to remember MacGyver, the 80s/90s DIY action hero that could free himself from any hopeless situation only with the help of a shoelace, a cucumber and a lighter? Good old times. Now imagine a location-based virt... |
| - | Creathor Ventures invests in alarm and crisis management start-up Serinus | Bad Homburg/Hagen March 5, 2019 – Creathor Ventures invests one million euros in Serinus, a provider of alarm and crisis management solutions based in Hagen/Germany. In critical situations, Serinus' software automatically alerts the respons... |
| - | vasopharm Closes € 9.5 million Financing Round | Würzburg, Germany – July 11, 2019: vasopharm GmbH, a private biopharmaceutical company developing a novel treatment for traumatic brain injury (TBI), today announced the successful completion of a €9.5 million financing co-led by Heidelberg... |
